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Dissecting human antibody responses:
useful, basic and surprising findings
Antonio Lanzavecchia
Human memory B cells and plasma cells
represent a rich source of antibodies that
have been selected in response to human
pathogens. In the last decade, different
methods have been developed to interrogate
the human memory repertoire and isolate
monoclonal antibodies. I will discuss how a
target-agnostic approach based on high-
throughput screening of antibodies produced
by cultured B cells and plasma cells has not
only provided potent and broadly neutraliz-
ing antibodies against a range of pathogens,
but has also advanced our understanding of
basic aspects of the immune response, from
host–pathogen interaction to the role of
somatic mutations in affinity maturation
and in the diversification of the antibody
response. Most surprisingly, this approach
has also revealed a new mechanism of diver-
sification based on templated insertion of
non-Ig DNA into antibody genes that we
discovered in the context of the immune
response to malaria infection.
A trove of antibodies
M emory B cells represent therepository of the immune experi-ence of an individual. They are
selected in the germinal centres, where they
undergo a process of somatic mutations and
selection by antigen and T helper cells.
Memory B cells persist for a life time and
can rapidly respond to a booster immuniza-
tion by generating large numbers of plasma
cells that are transiently present in the blood
and localize to surviving niches in the bone
marrow as long-lived plasma cells that are
the main source of serum antibodies.
The interrogation of memory B cell and
plasma cell repertoires of humans offers
unique opportunities. As compared to mice,
humans are naturally exposed to their own
pathogens, often through recurrent infections,
and are therefore a better source of antibodies
that target the most relevant antigens and can
reveal mechanisms of host–pathogen interac-
tion. Furthermore, given the genetic variabil-
ity of the human population and the
idiosyncrasies of the immune response, some
individuals may generate antibodies with
unusual potency or breadth. Finally, studies
of the antibody response in humans can shed
light on basic aspects of the immune response,
such as the role of somatic mutations and the
mechanisms that underpin the generation of
broadly neutralizing antibodies or autoanti-
bodies, and possibly uncover examples of
such mechanisms that may be uniquely devel-
oped or better identified in humans.
A target-agnostic approach to identify
functional antibodies
In the last decade, several methods have been
developed to isolate human monoclonal anti-
bodies. In principle, they come down to two
basic approaches. The first approach consists
of the isolation of single antigen-specific
B cells using a fluorescently tagged antigen as
a bait, followed by cloning of immunoglobu-
lin genes and expression of the recombinant
antibodies in a cell line. This method is very
effective, but requires that the target antigen
is known and available in a purified form. In
my laboratory, we developed an alternative
approach based on high-throughput screening
of the antibodies produced by cultured B cells
or plasma cells (Fig 1A). Memory B cells from
selected donors are immortalized with high
efficiency (>30%) by combining Epstein–Barr
virus (that delivers signal 1 and signal 2) with
a TLR7 or TLR9 agonist (that delivers signal 3
required for potent activation of memory B
cells) (Traggiai et al, 2004). The immortalized
B cells proliferate and secrete large amounts
of antibodies in the culture supernatant. Anti-
gen-specific plasma cells recovered following
a booster immunization have lost prolifera-
tive capacity, but can be kept alive in cultures
supplemented with IL-6 and stromal cells. In
these cultures that mimic the survival niches
of the bone marrow, a single plasma cell
secretes antibodies at a constant rate of
100 pg/day (Corti et al, 2011). To facilitate
the isolation of specific antibodies and the
cloning of the VH/VL genes, both immortal-
ized B cells and plasma cells are seeded in
clonal conditions and cultures are handled
with an automated liquid handling system.
There are distinctive advantages in screening
the repertoire of secreted antibodies. The
first is that the approach is target-agnostic,
since screening can be done using func-
tional assays, such as virus neutralization,
without a priori knowledge of the target
antigens, using even whole bacteria or para-
sites. Second, it is well suited to identify
antibodies that cross-react with different
antigens, since parallel screenings can be
performed against multiple targets. Third, it
bypasses the need to sequence and express
large numbers of antibody sequences since
cells of interest are selected based on the
initial screenings.
Neutralizing antibodies for passive
vaccination and vaccine design
A relevant example of the utility of the
target-agnostic approach comes from a study
of the antibody response to human cytome-
galovirus (HCMV), a complex herpesvirus
expressing 20 different surface glycoproteins
that causes serious pathology in the foetus
and in immunocompromised patients. By
screening for the capacity to neutralize the
wild-type virus, we isolated antibodies that
were 1,000-fold more potent than antibodies
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to the fusion protein gB and identified their
viral target as a pentameric complex formed
by gH, gL, pUL128, pUL130 and pUL131A.
We then produced a soluble form of this
pentamer and found that it can elicit, in
mice, neutralizing antibody titres that
exceeded by more than 100-fold those
induced in humans by natural infection
(Kabanova et al, 2014). These studies illus-
trate a general approach of “analytic vacci-
nology” where the neutralizing antibodies
are used for the identification of the target
antigen and for the quality control of the
recombinant vaccine.
The possibility of performing parallel
screening against multiple targets was instru-
mental for the identification of broadly reac-
tive antibodies capable of neutralizing
multiple viruses. These include the antibod-
ies FI6 and FY1, which bind to conserved
epitopes in the stem region of influenza
hemagglutinin (HA) and neutralize all influ-
enza A viruses (Corti et al, 2011; Kallewaard
et al, 2016), and MPE8, an antibody that
binds to a unique conserved site on the
pre-fusion form of the F protein and neutral-
izes four different paramyxoviruses, includ-
ing human RSV and MPV (Corti et al, 2013).
These antibodies are promising candidates
for prophylaxis and therapy of infections
since they trigger effector functions and
target conserved structures, thus limiting the
possibility of selecting escape mutants. In
addition, they represent useful tools for the
design of stabilized pre-fusion glycoprotein
vaccines.
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Figure 1. Dissecting human antibody responses to influenza virus: VH-gene polymorphism and somatic mutations.
(A) Target-agnostic approaches to interrogate human memory B cell or plasma cell repertoires based on high-throughput screening of clonal cultures. (B) Protein distance of
influenza A HA subtypes; H1 (group 1) and H3 (group 2) share only 35% amino acid identity. (C) Public antibodies that neutralize group 1 influenza viruses use VH1-69 alleles
with F54 and have a 13-amino acid HCDR3with Y98 (black lines). They can achieve high affinity through a single P52aA mutation (red). Shown are the functional properties of
the UCA, of the first branch point (BP) and of a mature antibody (FI225) carrying several redundant mutations. (D) Schematic view of the developmental pathway of pan-
influenza neutralizing antibodies. A high-affinity precursor specific for group 1 viruses (H1N1) generates, through somatic mutations, a variant that is expanded by
stimulation with a group 2 virus (H3N2) in the absence of further mutations.
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A straightforward application of the
method lies in the rapid isolation of neutraliz-
ing antibodies against emerging pathogens,
such as Ebola virus, SARS (Traggiai et al,
2004) and MERS coronaviruses. In the case of
MERS, it was possible, in only 4 months, to
go from a sample of memory B cells to
preclinical validation of a neutralizing anti-
body and the generation of a cell line produc-
ing the antibody in grams/L amounts. Similar
studies on Dengue and Zika viruses defined
different classes of antibodies endowed with
neutralizing or infection-enhancing activity.
V-gene polymorphism and somatic
mutations shaping antibody responses
The interrogation of the memory B-cell
repertoire offers the opportunity to investi-
gate, in biologically and medically relevant
settings, fundamental aspects of the human
immune response, such as the relative
contribution of germ line V-gene polymor-
phism, VDJ junctional diversity and somatic
mutations to antigenic specificity. An inter-
esting example comes from the study of anti-
bodies that neutralize group 1 influenza
viruses and that are produced by most indi-
viduals following infection or vaccination.
As reported by several laboratories, these
“public” antibodies use VH1-69 and bind,
exclusively through the VH, to a conserved
region in the HA stem. By isolating a large
number of sister clones and by performing a
genealogical analysis of different clonal
families, we found that the unmutated
common ancestors (UCA) have low affinity
for group 1 HA and do not neutralize infec-
tion (Fig 1B and C). Remarkably, the first
branch points acquire through a single
P52aA mutation in HCDR2, high affinity and
neutralizing activity, comparable to that of
the antibodies isolated from memory B cells
that carried up to 15–30 amino acid substitu-
tion (Pappas et al, 2014). These findings
demonstrate that affinity maturation can be
achieved rapidly, through a single mutation,
and that numerous and redundant somatic
mutations continue to accumulate, providing
an extensive diversification within the prolif-
erating clone. Interestingly, in these anti-
bodies, a critical contact residue, F54, is
germline-encoded, but this position is dimor-
phic, with different alleles carrying either F
or L. Consequently, individuals who lack a
F54-encoding allele cannot produce the
public VH1-69 antibody response, while
individuals that have a F54 allele have a
high frequency of precursors, with the only
additional requirement being a 13-amino
acid HCDR3 with a Y98 that makes a critical
contact site with the antigen. These findings
underline the impact that VH-gene polymor-
phism can have on the antibody response
and suggest that certain alleles may play the
role of immune response (Ir) genes and
become positively selected in the population
exposed to a given pathogen.
The genealogical analysis of the two pan-
influenza neutralizing antibodies, FI6 and
FY1, showed that the corresponding UCAs
have already high binding affinity and
neutralizing activity, but only on group 1
viruses and acquire the capacity to neutralize
group 2 viruses through somatic mutations
(Kallewaard et al, 2016). These findings are
consistent with a model where pan-influenza
neutralizing antibodies arise from the prim-
ing of high-affinity precursors by a group 1
virus (in this case H1N1), followed by
somatic mutations and generation of a vari-
ant with broader reactivity to group 2 viruses
that can be boosted by a group 2 virus such
as H3N2 (Fig 1D). Importantly, the isolation
of cells producing the identical FI6 antibody
for 4 consecutive years in response to vacci-
nation or infection indicates that secondary
antibody responses are to a large extent inde-
pendent from germinal centres, a factor that
allows the antibody to retain the original
specificity. The genealogical analysis of the
neutralizing antibody MPE8 revealed a simi-
lar mechanism, with the UCA possessing
high affinity for RSV only and MPE8 acquir-
ing cross-reactivity to MPV through somatic
mutations (Corti et al, 2013).
The extensive antibody diversification
observed in humans can increase antibody
affinity and promote breadth, but comes at
the price of generating many new specificities
that may cross-react with self-antigens. The
notion that autoantibodies can be generated
by somatic mutations is supported in
humans by the finding that the UCAs of
autoantibodies specific for desmoglein 3 or
GM-CSF found in patients with severe
autoimmune diseases do not bind to the
respective self-antigens (Di Zenzo et al,
2012; Piccoli et al, 2015). Thus, it is tempting
to speculate that these autoantibodies may
have been generated by somatic mutations
in B-cell clones responsive to a foreign anti-
gen in the absence of structural mimicry.
Importantly, the mechanisms of deletion or
anergy that restrain naı¨ve autoreactive B
cells may not apply to activated/memory B
cells, which have different triggering require-
ment and can traffic to peripheral tissues.
A surprising finding: antibodies
generated by templated insertions
As mentioned above, the target-agnostic
approach is especially suited to dissect the
antibody response to complex pathogens in
the absence of a detailed knowledge of the
target antigens. We were interested in identi-
fying antibodies that could broadly recognize
the variant surface antigens (VSAs) of Plas-
modium falciparum, the parasite causing
malaria, which are expressed on the surface
of infected erythrocytes (IEs). VSAs mediate
adhesion of IEs to endothelia and are targets
of antibodies that control disease, but their
high number (>200 genes), their extensive
polymorphism and their clonal expression
provide the pathogen with a powerful chame-
leon-like escape strategy.
Out of a large Kenyan cohort, we initially
selected two individuals with serum antibod-
ies that cross-agglutinated erythrocytes
infected by different P. falciparum strains.
From their memory B cells, we isolated a
panel of broadly reactive monoclonal antibod-
ies using staining of infected erythrocytes as a
screening strategy. Surprisingly, all the
broadly reactive antibodies had a unique
structure, since they carried a large insert
between the V and the DJ segments. The
inserts, of approximately 400 bp, comprised
the exon encoding the extracellular domain of
the collagen-binding inhibitory receptor
LAIR1/CD305, encoded in the leucocyte
receptor cluster on Chr. 19 (Tan et al, 2016).
Given the insertion between V and DJ, the
LAIR1 domain is positioned at the tip of the
HCDR3 (Fig 2A and B). The target antigens of
LAIR1-containing antibodies were identified
in some members of the RIFINs, a family of
polymorphic VSAs expressed on the surface of
IEs (Fig 2C). Importantly, the inserted LAIR1
domain was both necessary and sufficient for
binding to RIFINs, as demonstrated by its
insertion into an irrelevant antibody or by the
production of LAIR1-Ig fusion proteins.
To investigate how frequently LAIR1-
containing antibodies are produced, we
screened two additional cohorts from Mali
and Tanzania and found that up to 10% of
the individuals have such antibodies in the
serum (Pieper et al, 2017). This study led
not only to the isolation of more LAIR1-
containing monoclonal antibodies, but also
to the finding of a new insertion modality
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where the LAIR1 exon with 50 and 30 intronic
sequences is inserted into the immunoglobu-
lin switch region. This insertion leads, by
exon shuffling, to the production of the orig-
inal antibody and of a bispecific antibody
containing the LAIR1 domain precisely
placed at the elbow between the VH and
CH1 domains (Fig 2A and B). In one case,
the LAIR1 insertion in the switch region was
accompanied by the genomic deletion of VH
and CH1, generating a “camel-like” LAIR1-
containing antibody.
In each individual analysed so far, the
LAIR1-containing antibodies dominate the
response to IEs and are produced by a single
B-cell clone that contains a unique insert
and undergoes extensive expansion and
somatic mutations, thus demonstrating an
extraordinary fitness. Somatic mutations in
LAIR1 were more frequent when the inser-
tion was at the V-DJ junction, which is
continually targeted by AID in germinal
centres, and less frequent when the insertion
was in the switch region, which is only
transiently targeted by AID during switch
recombination. Interestingly, somatic muta-
tions in the LAIR1 domain eliminate collagen
binding and modulate affinity and cross-reac-
tivity with different RIFINs. The finding that
collagen binding was always lost, even when
the somatic mutation mechanism was less
effective, suggests that loss of self-reactivity
is a prerequisite for expansion of B cells
making LAIR1-containing antibodies.
The insertion of non-VDJ sequences
encoding structured domain into Ig genes is a
new and potentially general concept. Our
finding was facilitated by the huge expansion
of LAIR1-containing B cells and by the
unique properties of the antibodies made. In
an initial attempt to determine the generality
of this phenomenon, we found frequent
insertions in the switch region of memory B
cells from European blood donors. Interest-
ingly, the inserts largely originate from genes
that are transcribed in B cells and are
encoded in virtually all chromosomes and, in
rare cases, comprised exons with frames
compatible with expression (Fig 2D).
Malaria infection can cause chromosomal
instability and translocations involving the
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Figure 2. Antibody diversification by templated insertions.
(A) The LAIR1 exon, flanked by short intronic sequences, is inserted in the V-DJ junction or in the switch region. Somatic mutations (red lines) abolish collagen binding and
increase binding to the malaria antigens RIFINs. (B) Schematic representation of the corresponding antibodies with the LAIR1 domain inserted at the tip of HCDR3 or at the
VH-CH1 elbow. (C) RIFINs bind to inhibitory receptors, including LAIR1, and represent a mechanism of parasite immune evasion. LAIR1-containing antibodies bind to RIFINs
on IEs, preventing their interaction with cellular LAIR1 and targeting IEs for destruction. (D) Templated inserts derived from transcribed genes encoded in different
chromosomes are frequently found in the switch region of memory B cells in European blood donors (reproduced with permission from Pieper et al (2017)).
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switch region, suggesting that it may also
play a causative role in the generation of
templated insertions. However, the finding
of frequent templated insertions in European
blood donors is more consistent with a
general mechanism that remains to be
molecularly defined. The sites of insertion
suggest a mechanism of patch-repair of DNA
double-strand breaks induced by either RAG
or AID during V-DJ recombination or class
switch. The integrity of the genomic LAIR1
loci in B-cell clones producing LAIR1-
containing antibodies suggests a copy-and-
paste mechanism. In view of the finding that
the inserts contain intronic sequences and
are derived from expressed genes, we favour
the hypothesis that the templated DNA may
originate from the resolution of stalled repli-
cation forks caused by a clash between tran-
scription and DNA replication.
Receptor-based antibodies: emerging
data for an old concept
Our findings suggest that the insertion of
templated DNA represents a novel and
general mechanism of antibody diversification
that can provide a broad range of protein
domains to be further diversified by somatic
mutations. As exemplified by LAIR1, the
insertion of a domain encoding a pathogen
receptor can generate public antibodies that
are effective against the pathogen. Distinctive
advantages of these receptor-based antibodies
lie in the broad recognition of all pathogen
variants, leaving no room for the selection of
escape mutants, and in the possibility of diver-
sifying the receptor domain through somatic
mutations to increase binding to pathogen
and decrease self-reactivity. The new antibod-
ies are reminiscent of Ehrlich’s “side-chain”
theory of antibody production, where the anti-
body was essentially a secreted form of the
receptor for the pathogen. We predict that
other examples of receptor-based antibodies
will be found in response to a variety of human
pathogens. Besides LAIR1, other candidates for
the generation of receptor-based antibodies
to P. falciparum are ICAM1, an adhesion
molecule that binds to IEs, and LILRB1, an
inhibitory receptor that, like LAIR1, has
been shown to bind to RIFINs. Similarly,
insertions of ICAM1 or SLAM domains may
generate receptor-based antibodies that
neutralize rhinoviruses or measles virus.
As a final remark, we realize that, by
uncovering the ingenuity of Nature, we have
learned new ways to engineer antibodies and,
possibly, to edit antibodies in primary B cells
using the endogenous AID activity. We also
discovered how strong antibody responses
can be generated by a single B-cell clone, rais-
ing a case for adoptive B-cell therapy.
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